Sanofi (SNYNF)

OTCMKTS · Delayed Price · Currency is USD
96.00
-0.24 (-0.25%)
Dec 10, 2025, 11:43 AM EST
0.17%
Market Cap117.87B
Revenue (ttm)53.89B
Net Income (ttm)10.69B
Shares Outn/a
EPS (ttm)8.67
PE Ratio11.02
Forward PE10.13
Dividendn/a
Ex-Dividend Daten/a
Volume564
Average Volume21,067
Open96.00
Previous Close96.24
Day's Range96.00 - 96.00
52-Week Range90.05 - 122.03
Beta0.37
RSI44.45
Earnings DateJan 29, 2026

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange OTCMKTS
Ticker Symbol SNYNF
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial numbers in EUR Financial Statements

News

Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks

U.S. regulators are taking a fresh look at infant respiratory syncytial virus (RSV) antibody treatments after concerns raised by vaccine skeptics prompted Robert F. Kennedy Jr.'s health leadership tea...

1 day ago - Benzinga

SNY Analyst Downgrades: Sanofi Receives Neutral Rating from Guggenheim | SNY Stock News

SNY Analyst Downgrades: Sanofi Receives Neutral Rating from Guggenheim | SNY Stock News

1 day ago - GuruFocus

Sanofi (SNY) Downgraded by Guggenheim Analyst Amidst Pipeline Concerns

Sanofi (SNY) Downgraded by Guggenheim Analyst Amidst Pipeline Concerns

1 day ago - GuruFocus

Sanofi (SNY) Downgraded to Neutral by JP Morgan | SNY Stock News

Sanofi (SNY) Downgraded to Neutral by JP Morgan | SNY Stock News

2 days ago - GuruFocus

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public he...

5 days ago - Reuters

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi

Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.

5 days ago - Nasdaq

3 Large Drug Stocks to Watch as the Industry Shows Some Recovery

In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.

6 days ago - Nasdaq

Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”).

6 days ago - GlobeNewsWire

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

LONDON--(BUSINESS WIRE)-- #AI--LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic anti...

6 days ago - Business Wire

Sanofi SA at Citi Global Healthcare Conference Transcript

Sanofi SA at Citi Global Healthcare Conference Transcript

6 days ago - GuruFocus

Why Falcon's Beyond Stock Is Jumping Today

Falcon’s Beyond Global, Inc. (NASDAQ: FBYD) traded higher on Tuesday after the company announced its placement on the preliminary list for possible inclusion in the Russell 2000 Index. FTSE Russell p...

8 days ago - Benzinga

Notable healthcare headlines for the week: Sanofi, Eli Lilly, and Novo Nordisk in focus

Get the latest healthcare stock updates, key drug price negotiations, and policy changes impacting the S&P 500.

10 days ago - Seeking Alpha

Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation

Sanofi stock dropped Wednesday after French authorities raided the drugmaker's Paris headquarters as part of a tax fraud investigation.

14 days ago - Investor's Business Daily

AI won't cure cancer, says Sanofi CEO

Paul Hudson, CEO of pharmaceuticals giant, Sanofi discusses the benefits and limitations of implementing AI across the healthcare sector.

14 days ago - CNBC

Sanofi (SNY) Headquarters Raided in Tax Fraud Investigation

Sanofi (SNY) Headquarters Raided in Tax Fraud Investigation

14 days ago - GuruFocus

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe

Sanofi SA's (NASDAQ: SNY) Paris headquarters received an unannounced visit on Tuesday as tax investigators, accompanied by prosecutors and specialist aides, searched the site amid a widening financial...

15 days ago - Benzinga

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe

Sanofi SA's (NASDAQ: SNY) Paris headquarters received an unannounced visit on Tuesday as tax investigators, accompanied by prosecutors and specialist aides, searched the site amid a widening financia...

15 days ago - Benzinga

Sanofi Paris HQ raided over tax fraud investigation involving Societe Generale

Sanofi's Paris HQ raided over tax fraud probe tied to Societe Generale financing. Read more here.

15 days ago - Seeking Alpha

Sanofi (SNY) Investigated for Tax Fraud and Money Laundering

Sanofi (SNY) Investigated for Tax Fraud and Money Laundering

15 days ago - GuruFocus

SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria

Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.

15 days ago - Nasdaq

Sanofi (SNY) Gains EU Approval for Dupixent in Chronic Urticaria

Sanofi (SNY) Gains EU Approval for Dupixent in Chronic Urticaria

15 days ago - GuruFocus

Sanofi (SNY) Gains European Nod for Dupixent in Treating Chronic Urticaria

Sanofi (SNY) Gains European Nod for Dupixent in Treating Chronic Urticaria

15 days ago - GuruFocus